1. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase
by Jiří Pavlů, Andrea K. Kew, Beatrice Taylor-Roberts, Holger W. Auner, David Marin, Eduardo Olavarria, Edward J. Kanfer, Donald H. MacDonald, Dragana Milojkovic, Amin Rahemtulla, Katayoun Rezvani, John M. Goldman, Jane F. Apperley, and Richard M. Szydlo
Blood
Volume 115(20):
May 20, 2010
©2010 by American Society of Hematology

2. Nonrelapse mortality and survival.
Nonrelapse mortality and survival. Probabilities of nonrelapse mortality (A-B) and overall survival (C-D) stratified by hematopoietic stem cell transplantation comorbidity index (HCT-CI; 0 vs > 0; A,C) and preconditioning C-reactive protein (CRP) levels (0-9 mg/L vs > 9 mg/L; B,D).
Jiří Pavlů et al. Blood 2010;115:
©2010 by American Society of Hematology